Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51

Gene therapy may be nearing 'major breakthrough,' Baron's says

Gene therapy is rapidly emerging as one of the most exciting areas in biotechnology, and generating new hope for patients with rare and often deadly inherited diseases, Andre Bary writes in this week's edition of Barron's. The first regulatory approval for replacement gene therapy could come as soon as January, if the FDA gives the go-ahead to Spark Therapeutics (ONCE) for its one-time treatment that targets a rare, inherited retinal condition leading to blindness, he adds. Other publicly traded companies developing treatments in this area include AveXis' (AVXS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), and Voyager Therapeutics (VYGR).Reference Link

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

ONCE Spark Therapeutics
$85.15

-1.95 (-2.24%)

09/21/17
JEFF
09/21/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Spark rallying 5%-7% on positive FDA panel
Jefferies analyst Michael Yee sees a "high likelihood" for a positive FDA panel on October 12 for Spark Therapeutics' SPK-RPE65, setting up approval for the first gene therapy drug for rare blindness on or before the FDA action date of January 12, 2018. The analyst sees 5%-7% share upside on a positive vote, mostly as a "de-risking event and also a positive read-through derivative to gene therapy companies as FDA starts to approve gene therapy drugs." He keeps a Buy rating on Spark with a $95 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $100
RBCM
Outperform
Spark Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler started Spark Therapeutics with an Outperform rating and $100 price target. The analyst sees the expected upcoming approval of Luxturna as having "broad positive read-through" to the company's platform. He's a buyer ahead of next month's FDA panel.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark named top pick in U.S. SMid-Cap Biotechnology at Barclays
Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Spark Therapeutics with an Overweight rating and $104 price target. The analyst views the company's Luxturna as a potential disruptive treatment in inherited retinal dystrophies.
AVXS AveXis
$92.11

-4.03 (-4.19%)

09/14/17
RBCM
09/14/17
INITIATION
Target $92
RBCM
Sector Perform
AveXis initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started AveXis with a Sector Perform rating and $92 price target.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
AveXis initiated with an Overweight at Barclays
Barclays initiated AveXis with an Overweight rating and $124 price target, citing AVXS-101 showing "impressive" clinical benefit in Ph1/2 study, which could result in it becoming a strong competitor to Spinraza.
08/29/17
08/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Esperion (ESPR) initiated with an Outperform at Northland. 2. Carter's (CRI) initiated with an Outperform at Macquarie. 3. DarioHealth (DRIO) initiated with a Buy at Aegis. 4. Helen of Troy (HELE) initiated with an Underperform at BofA/Merrill. 5. AveXis (AVXS) initiated with a Reduce at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RGNX Regenxbio
$28.25

-1.15 (-3.91%)

08/16/17
EVER
08/16/17
INITIATION
Target $25
EVER
Outperform
Regenxbio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Regenxbio with an Outperform and a $25 price target.
09/05/17
CHDN
09/05/17
NO CHANGE
Target $75
CHDN
Buy
Regenxbio price target raised to $75 from $55 at Chardan
09/19/17
SBSH
09/19/17
DOWNGRADE
Target $5.5
SBSH
Sell
Dimension Therapeutics downgraded to Sell from Neutral at Citi
Citi analyst Joel Beatty downgraded Dimension Therapeutics (DMTX) to Sell saying his base case is now the takeover proposed by Ultragenyx (RARE) will go ahead. Since Dimension s currently trading at a small premium to the $5.50 per share proposal, the analyst downgraded the stock to Sell. Beatty sees a "small but real potential" for a higher bid to come in. He believes, however, that a successful bid from Regenxbio (RGNX) would likely need to be double its original offer. The analyst raised his price target for Dimension shares to $5.50 from $3.41.
09/19/17
BARD
09/19/17
NO CHANGE
BARD
Outperform
Ultragenyx deal for Dimension would be good strategic fit, says Baird
Baird analyst Michael Ulz noted Ultragenyx (RARE) topped Regenxbio's (RGNX) bid for Dimension Therapeutics (DMTX) with a $5.50 per share offer of its own. He views the proposed acquisition of Dimension as a good strategic fit that would add a gene therapy platform and expand the early-stage pipeline. Ulz keeps an Outperform rating on Ultragenyx shares.
BOLD Audentes Therapeutics
$27.31

-0.1 (-0.36%)

10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
05/01/17
LEER
05/01/17
INITIATION
Target $22
LEER
Outperform
Audentes Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Audentes Therapeutics with an Outperform rating and $22 price target as he believes catalysts over the next 12 months have the potential to generate enthusiasm for the company's approach, which appears de-risked by strong preclinical animal model data.
08/16/17
EVER
08/16/17
INITIATION
Target $23
EVER
Outperform
Audentes Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Audentes Therapeutics with an Outperform and a $23 price target.
VYGR Voyager Therapeutics
$17.50

-0.22 (-1.24%)

03/01/17
NOMU
03/01/17
INITIATION
Target $31
NOMU
Buy
Voyager Therapeutics initiated with a Buy at Nomura
Nomura initiated Voyager Therapeutics with a Buy and a $31 price target.
03/31/17
STFL
03/31/17
NO CHANGE
STFL
Voyager Therapeutics has reached attractive entry point, says Stifel
After meeting with Voyager's CEO, Stifel analyst Katherine Breedis says that the company "continues to make solid progress" with its top drug, VY-AADC01. The analyst notes that the company is slated to report Phase 1B six month data for the drug in the middle of this year, and she says that it could be an important positive turning point for the shares. The analyst adds that the data may have been "de-risked" by recent improved outcomes reported by the company. Breedis thinks that VY-AADC01 has several key potential positive catalysts over the next 6-9 months,. She thinks that the stock has reached an attractive entry point and keeps a $33 price target and a Buy rating on the stock.
07/28/17
STFL
07/28/17
INITIATION
STFL
Buy
Voyager Therapeutics coverage resumed with a Buy at Stifel
Stifel analyst Thmas Shrader resumed coverage of Voyager with a $20 price target and a Buy rating. He thinks that the company's lead drug, a treatment for Parkinson's "has great promise."
08/16/17
EVER
08/16/17
INITIATION
Target $21
EVER
Outperform
Voyager Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Voyager Therapeutics with an Outperform and a $21 price target.

TODAY'S FREE FLY STORIES

05:30
10/23/17
10/23
05:30
10/23/17
05:30
General news
FX Action: USD-JPY has remained settled under 114.00 »

FX Action: USD-JPY has…

NVS

Novartis

$85.74

-0.42 (-0.49%)

05:29
10/23/17
10/23
05:29
10/23/17
05:29
Hot Stocks
Novartis receives FDA Breakthrough Therapy Designation for Tafinlar/Mekinist »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 17

    May

BA

Boeing

$264.75

5.71 (2.20%)

05:25
10/23/17
10/23
05:25
10/23/17
05:25
Hot Stocks
Boeing, Mitsubishi Heavy reach agreement on cost reduction for 787 production »

Boeing and Mitsubishi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BAC

Bank of America

$27.17

0.59 (2.22%)

05:24
10/23/17
10/23
05:24
10/23/17
05:24
Hot Stocks
Merrill Lynch fined $45.5M in Britain for not reporting derivative transactions »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATHN

athenahealth

$126.04

9.63 (8.27%)

05:18
10/23/17
10/23
05:18
10/23/17
05:18
Upgrade
athenahealth rating change  »

athenahealth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$33.23

-0.835 (-2.45%)

05:13
10/23/17
10/23
05:13
10/23/17
05:13
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$48.37

0.24 (0.50%)

05:12
10/23/17
10/23
05:12
10/23/17
05:12
Downgrade
Rio Tinto rating change  »

Rio Tinto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$235.73

-0.27 (-0.11%)

05:02
10/23/17
10/23
05:02
10/23/17
05:02
Recommendations
MercadoLibre analyst commentary  »

MercadoLibre price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$338.10

-4.32 (-1.26%)

04:59
10/23/17
10/23
04:59
10/23/17
04:59
Initiation
Biogen initiated  »

Biogen assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CELG

Celgene

$121.33

-14.63 (-10.76%)

04:56
10/23/17
10/23
04:56
10/23/17
04:56
Downgrade
Celgene rating change  »

Celgene assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

ASOMY

ASOS

$74.28

1.5 (2.06%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
ASOS management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PAY

Verifone

$20.06

0.06 (0.30%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Verifone management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 14

    Dec

PLUG

Plug Power

$2.70

0.17 (6.72%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Plug Power to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 16

    Nov

DDAIF

Daimler AG

$80.57

-1.11 (-1.36%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

September Chicago Fed…

IVC

Invacare

$14.60

0.05 (0.34%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALXN

Alexion

$139.02

-1.44 (-1.03%)

04:54
10/23/17
10/23
04:54
10/23/17
04:54
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 06

    Nov

BIVV

Bioverativ

$60.22

0.49 (0.82%)

04:52
10/23/17
10/23
04:52
10/23/17
04:52
Initiation
Bioverativ initiated  »

Bioverativ assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

04:50
10/23/17
10/23
04:50
10/23/17
04:50
Downgrade
Tesaro rating change  »

Tesaro assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

AMAG

Amag Pharmaceuticals

$15.60

-0.45 (-2.80%)

04:48
10/23/17
10/23
04:48
10/23/17
04:48
Initiation
Amag Pharmaceuticals initiated  »

Amag Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 02

    Feb

  • 14

    Feb

04:15
10/23/17
10/23
04:15
10/23/17
04:15
General news
FX Action: USD-CAD has remained underpinned »

FX Action: USD-CAD has…

03:05
10/23/17
10/23
03:05
10/23/17
03:05
General news
FX Update: The dollar has traded mixed »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.